LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Biologics/Spine Firm Jumps Into Virus-Killing Mask Market
Biologics

Spine Firm Jumps Into Virus-Killing Mask Market

December 7, 2020 2 min read Premium comments

Advertisement

Spine Firm Jumps Into Virus-Killing Mask Market
Source: SINTX Technologies, Inc. and Wikimedia Commons and Tadeas Bednarz
Secondary#siliconnitride#sintx#viruskillingmask

SINTX Technologies, Inc., a manufacturer of spinal implants based in Salt Lake City, Utah, has discovered yet another use for its proprietary biomaterial silicon nitride—a mask that traps and inactivates respiratory viruses.

Company President Sonny Bal, M.D., M.B.A., J.D., Ph.D. told OTW, “Several years ago we discovered that silicon nitride spinal implants showed surface antibacterial properties, even as the surface chemistry of the material was ‘friendly’ toward human cells. Back in 2019 we conducted research demonstrating that silicon nitride may also work against viruses. We put this work ‘on the shelf,’ however, because at the time it was more of an intellectual curiosity.”

Fast forward to 2020, says Dr. Bal, and it was time to dust off that prior work.

“We had an inkling that silicon nitride would work against COVID-19 because it is a single-strand RNA virus. We participated in two studies, here in the USA, and one in Japan where exposure to silicon nitride did indeed result in the complete inactivation of the virus in under a minute. This opened the door to the development of a mask.”

So as to avoid the issue of breathing in the chemical compound, the company is working toward a special fabric that is impregnated with silicon nitrate. “We had to contend with the issue of how to get the material into the mask fabric. Too much heat would burn the fabric—too little and no bonding would occur. We are using a powdered solution that is engineered to distribute silicon nitride evenly all around, with particle clumping.”

Once SINTX overcame these technical barriers, the company created test samples and sent to them to an independent lab. Dr. Bal: “We contracted with academic and commercial enterprises to confirm the antiviral properties of silicon nitride particles, and are awaiting detailed test results from fabric testing. The next step is to move toward scaleup of the antiviral fabric manufacturing process.”

Partnering with veteran face mask makers O2TODAY, SINTX will scale up over the coming weeks and months. “We trust the integrity of our partners and independent labs. Ours is a unique device that not only captures, but captures and kills COVID-19 and other viruses such as SARS-CoV (severe acute respiratory syndrome). the herpes simplex virus, the influenza virus, and many more.”

“This pandemic has reminded us that we are a global community and that such things as pandemics can even happen here in the U.S. Given the worldwide travel density and population density these respiratory viruses can spread easily. We will surely need such important mask protection going forward.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy